Phase 3 Asthma Trial, Recruiting NCT06323213 Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Condition: Asthma
Back to Asthma

Phase 3 Asthma Trial, Recruiting

NCT06323213
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written agreement to take part before the study begins.
  • Adults aged 18 to 75 years old at the time of signing the consent form.
  • People who have had a confirmed diagnosis of asthma for at least one year before the screening visit.
  • People who have been diagnosed with asthma by a doctor and have been treated with an inhaled corticosteroid (a type of asthma preventer medication) plus at least one other asthma control medication for at least 6 months before screening.

Who may not be able to join:

  • People who have a known, clinically significant lung condition other than asthma.
  • People who have had a severe asthma attack within 4 weeks before being enrolled in the trial.
  • People who have any condition involving high levels of a certain type of white blood cell (eosinophils) other than asthma.
  • People who have a known, pre-existing serious heart or cardiovascular condition.
  • People who have other significant medical conditions that are not well controlled with standard treatment.
  • People who have active Hepatitis B, Hepatitis C, or HIV infection, as identified by blood tests at screening.
  • People who have an allergy or intolerance to a type of medication known as a monoclonal antibody.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Min Zhang, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phone: +86 18911301578

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
24 June 2024
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Annualized rate of severe exacerbation events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov